Kornimate/medical-research-clean huggingface dataset:
trac-er intervention to reduce risky alcohol use and hiv risk

Conditions: Risk Behavior; Alcohol Use Disorder; HIV Infections

Summary: ecological momentary interventions (emi), which use phones to deliver messages to reduce alcohol use and related risk behaviors during or prior to drinking events, can help to address triggers in real-time. gps tracking can determine when individuals visit places they have previously reported drinking or triggers to drink and then emi messages can be delivered upon arrival to prevent risky alcohol use. a mobile app has been developed that uses gps tracking to determine when individuals visit "risky" places and then delivers a survey asking what behaviors they engaged in while at the location. the goal of the proposed study is to use this app to enhance the tracking and reducing alcohol consumption (trac) intervention by delivering messages that encourage participants to employ strategies discussed during trac sessions when arriving at risky places. when they leave these places, they will complete a survey and breathalyzer reading in order to collect event-level self-report and biological data on alcohol use and hiv risk. if their breathalyzer result indicates alcohol use, they will receive harm reduction messaging. it is expected that combining trac with emi ("trac-er") will increase effectiveness by reinforcing topics discussed during these sessions, providing in-the-moment messaging to address triggers, and collecting real-time alcohol use data.

for this study, the investigators will enhance an existing mhealth intervention (trac) to reduce alcohol use among young adults at risk for hiv by combining the intervention with an app which delivers emi messages in real-time. upon enrollment, participants will be randomized into one of 3 arms: trac-er (emi messaging, trac intervention, and smartphone-based alcohol monitoring), trac (trac intervention and smartphone-based alcohol monitoring), or a comparison group (smartphone-based alcohol monitoring only). participants will be recruited from kentucky and connecticut through community-based recruitment and health clinics. preliminary data used for this study were collected from a study (pi: lauckner, k01aa02530) testing the trac intervention with people living with hiv/aids, which has shown promising preliminary results, with high feasibility, acceptability, and encouraging preliminary outcomes.

Eligibility criteria:
inclusion criteria: * is between the ages of 18-35 at the start of the study * owns a smartphone * has not been diagnosed with hiv * screens positively for at-risk alcohol use (score of 4 or higher on the audit-c, or report engaging in binge drinking at least once over the past 12 months). * meets criteria for pre-exposure prophylaxis (prep) or is identified as being at high risk for hiv (i.e., reports history of using prep/pep, reports unprotected sex, etc.) exclusion criteria: * do not speak english * are actively detoxifying from substances and need medical supervision * a score of 20 or greater on the alcohol use disorders identification test

Keywords: motivational interviewing behavior ecological momentary intervention emi trac mobile gps
respiratory muscle strength and exercise capacity in smokers

Conditions: COPD - Chronic Obstructive Pulmonary Disease

Summary: this cross-sectional study aims to evaluate the respiratory muscle strength and physical capacity of symptomatic adult smokers in muğla. the study population will be the patients who were admitted to the pulmonary outpatient clinic of muğla training and research hospital between july 2024 and december 2024. the primary outcome is the proportion of individuals with maximum inspiratory pressure (mip) below 80%. secondary outcomes include the 6-minute walk test (6mwt) distance, maximum expiratory pressure (mep), and copd assessment test (cat) scores. smokers will be categorized into copd, prism, and pre-copd groups. the study will adjust for bmi as a key confounder and assess the modifying effects of gender, smoking habits, and age. ethical approval and informed consent will be obtained, with data analysis focusing on descriptive statistics, comparative analysis, and regression models to understand the impact of smoking on respiratory health.


Eligibility criteria:
inclusion criteria: * at least 5 packages of cigarette smokers who have an appropriate pft done at our lab. (pulmonary function test must be performed at evaluable standards according to ers/ats guidelines) exclusion criteria: * respiratory infection at the time of measurement (upper or lower resp. tract, viral or bacterial infections) * presence of chronic respiratory diseases (asthma, ipf, bronchiectasis, \[except copd\]) * exacerbation due to chronic respiratory diseases (except mild copd exacerbation) * neuromuscular disease (als, guillain-bare syndrome, muscular dystrophies, myasthenia gravis) * restrictive pulmonary disease (ipf, sarcoidozis, progresif pulmonary fibrosis)

Keywords: prism pre-copd copd mip 6mwt
laparoscopic versus transabdominal ultrasound in morbidly obese patients

Conditions: Cholelithiasis; Ultrasonography; Laparoscopic Gastric Bypass

Summary: the objective of this study is to prospectively compare laparoscopic ultrasound to transabdominal ultrasound for the detection of gallbladder pathology in obese patients presenting for laparoscopic gastric bypass. we hypothesize that laparoscopic ultrasound will be more sensitive and specific for cholelithiasis than transabdominal ultrasound in morbidly obese patients.

asymptomatic cholelithiasis is a prevalent condition in obese patients presenting for bariatric surgery. transabdominal ultrasound (tau) remains the gold standard for detection of cholelithiasis. the sensitivity and specificity of transabdominal ultrasound for cholelithiasis reported in literature is between 88-97% and 97-99%, respectively. the ability to detect cholelithiasis with tau in the obese population may be inhibited due to the presence of increased subcutaneous and visceral fat. laparoscopic ultrasound (lu) has the potential to overcome these technical challenges. in an era of minimally invasive bariatric surgery, it has been suggested that routine preoperative ultrasound tau be performed for the detection of cholelithiasis since intraoperative palpation is not feasible. we hypothesize that laparoscopic ultrasound will be more sensitive and specific for cholelithiasis than transabdominal ultrasound in morbidly obese patients.

Eligibility criteria:
inclusion criteria: * morbidly obese patients undergoing elective laparoscopic roux-en-y gastric bypass exclusion criteria: * prior history of gallbladder surgery

Keywords: ultrasonography gallbladder cholelithiasis laparoscopic gastric bypass obesity bariatric surgery
predictive model to calculate the risk of rbc transfusion in elective brain tumours resections (tscorebtr)

Conditions: Brain Tumor Adult; Transfusion; Surgery

Summary: to validate a predictive model for the risk of receiving rbcs in this population. this model uses four preoperative values (haemoglobin levels, tumour volume, previous craniotomy in the same spot, and number of craniotomies foreseen). the investigators would like to create an online data collection tool and calculator.

observational study collecting data from different institutions and teams groups in spain. the investigators aim at validating one model (published in journal of neurosurgical anesthesiology) in different settings and populations to see if it can be accurately used to provide an opportunity to optimize both the patient and the surgical plan as well as to guide perioperative crossmatch and rbc orders. inclusion criteria - brain tumour (primary or metastatic) patients undergoing craniotomy for resection. exclusion criteria patients younger than 18 years old. urgent/emergent surgery. brain tumours not requiring full craniotomy. patients with blood conditions causing coagulation abnormalities. systemic disease associated with significant abnormalities in coagulation times (prothrombin time \ 50 sg). outcome the investigators aim at developing objective and simple criteria about the probability of requirements rbcs during a brain tumour resection surgery. this way we could create a simple tool that would help to optimize both the patient and the surgical plan as well as to guide perioperative crossmatch and rbcs orders. statistical analysis transfusion requirement predictive probability will be calculated as follows: 〖1/(1+e〗\^(-(5.7606 + \[-0.7037\*(ph in g/dl)+ 0.0103\*(btltv in mm3)+ 1.0558\*(nc)+ 0.6232\*(pc)\]))) ph: preoperative haemoglobin; btltv: brain tumour lesions total volume; nc: craniotomies number; pc: previous craniotomy. nt=1 if nt\>1, or 0; pc=1 if pc at the same site for resection (not only biopsy), or 0. model discrimination and calibration will be assessed with area under roc curve, and hosmer-lemeshow test with calibration plot, respectively. p\<0.05 will indicate statistical significance.

Eligibility criteria:
inclusion criteria: - brain tumour (primary or metastatic) patients undergoing craniotomy for resection. exclusion criteria: * patients younger than 18 years old. * urgent/emergent surgery. * brain tumours not requiring full craniotomy. * patients with blood conditions causing coagulation abnormalities. * systemic disease associated with significant abnormalities in coagulation times (prothrombin time \ 50 sg).

Keywords: predictive model risk of red blood cells concentrates transfusion brain tumours resections (primary or metastatic)
heartmate 3 elevate™ registry

Conditions: Heart Failure; Cardiovascular Disease; Ventricular Dysfunction

Summary: evaluate real-world experience of heartmate 3 (hm3) in post-approval setting.

the purpose of this post-market registry is to collect data and evaluate the real-world experience of the heartmate 3 left ventricular assist system (hm3 lvas) in a post-approval setting.

Eligibility criteria:
inclusion: 1. patient consented to registry data collection 2. patient has met the heartmate 3 commercially approved labeling indication and is implanted with the hm3.

Keywords: heartmate 3 lvas lvad heart-assist devices thoratec corporation
preoperative nicotine cessation for women with breast cancer recommended for reconstruction

Conditions: Breast Cancer

Summary: close to 20% of cancer patients currently use nicotine products. nicotine use in breast cancer patients is associated with poorer overall outcomes, including worsened survival and increased surgical complications. nicotine cessation is rarely addressed in breast cancer patients at the time of diagnosis and may be a missed opportunity to optimize patient outcomes. patients that use nicotine products are not offered reconstruction at time of mastectomy or oncoplastics at the time of lumpectomy, which can be emotionally distressing in women with breast cancer. reconstruction could be an additional motivating factor in nicotine cessation success. this study aims to evaluate the feasibility of a nicotine cessation program designed by area health education center (ahec) in the target population. the study is designed to test the acceptability, and preliminary efficacy of a formal nicotine cessation program in women actively using nicotine products with breast cancer recommended for reconstructive or oncoplastics surgery.


Eligibility criteria:
inclusion criteria: * adults ≥ 18 years of age and ≤ 80 years of age. * women who are diagnosed with stage 0 - 3 breast cancer confirmed by biopsy * women who have been recommended to have reconstruction at time of mastectomy or oncoplastics at time of lumpectomy * participants who actively use nicotine products defined as any self-reported nicotine use within the past month * participant agrees to comply with all the study-related procedures. exclusion criteria: * patients not eligible for reconstruction or oncoplastics for other reasons including bmi\>35 or inflammatory breast cancer or based on surgeon discretion. * prisoners or subjects who are involuntarily incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness. * patients unable to complete the sessions because of language, travel or technology barriers * patients already actively participating in another cessation program * patients who are pregnant.

Keywords: breast cancer nicotine cessation mastectomy reconstruction smokers
insight (r)xt. indications for diagnosis, arrhythmia and monitoring of reveal xt

Conditions: Atrial Fibrillation; Cardiac Arrhythmias

Summary: to describe the clinical indications for reveal xt in diagnosis and continuous monitoring of arrhythmia and to explore the clinical applications and outcome of arrhythmia monitoring on patient care.

improving the diagnosis and management of cardiac rhythm disturbances remains a major challenge for physicians. limitations of current cardiac arrhythmia monitoring using ecg, holters or event recorders are that these methods are non-continuous and/or automatic arrhythmia detection is often impossible. the medtronic reveal xt insertable cardiac monitor is a programmable device which continuously monitors the patient's subcutaneous ecg and provides information regarding arrhythmia episodes, long term trending of af burden, patient's activity and heart rate variability. the reveal xt records cardiac information in response to patient activation and automatically detected arrhythmias thereby offering advantages over conventional tools for long-term arrhythmia monitoring with regard to compliance and recording time. the clinical applications for reveal xt are varied. diagnostic, arrhythmia monitoring and arrhythmia management functions can be discriminated. this study is a prospective, observational, multicenter international post-market study. the results of this study will describe the different patient groups for which the reveal xt is being used for the diagnosis and monitoring of various cardiac arrhythmias. this study will also collect data regarding the clinical consequences of using the reveal xt and the influence of reveal xt data on clinical care pathways. the physician as well as the patient's satisfaction with the device will be evaluated. the study will be conducted in 60-100 centers primarily in europe. it is expected that 800-1000 patients will be enrolled.

Eligibility criteria:
inclusion criteria: * patient implanted or scheduled for an implant with a reveal xt insertable cardiac monitor system for arrhythmia diagnosis or monitoring * patient must be willing to sign a patient data release form (or informed consent where applicable) exclusion criteria: * enrollment outside a 30-day window from the planned/performed reveal xt implant procedure (from 15 days pre-implant until 15 days post implant) * patient is implanted with a pacemaker, icd, crt-device or an implantable hemodynamic monitoring system * unwillingness or inability to cooperate or give written informed consent or, if the patient is a minor and the legal guardian refuses to give consent

Keywords: atrial fibrillation risk of cardiac arrhythmias loop recorder
the effect of an experimental gel based on acmella oleracea extract in reducing post-bleaching tooth sensitivity

Conditions: Tooth Bleaching; Pain; Dentin Desensitizing Agents

Summary: this randomized, double-blind clinical trial aimed to evaluate the effect of an experimental gel containing 10% jambu extract (acmella oleracea) in reducing postoperative tooth sensitivity caused by bleaching with 35% hydrogen peroxide. the volunteers of this study were randomized into two different groups - ge (a. oleracea extract at 10%) and gp (placebo). the dental elements of the ge received application of the experimental desensitizing gel on the buccal surfaces of the central incisors, lateral incisors, canines and upper and lower premolars, with a rubber cup in an active way, for 10 minutes. the gp group also received the application of a placebo gel (without active ingredient), under the same conditions described for the experimental gel. subsequently, all groups underwent in-office bleaching treatment with 35% hydrogen peroxide.post-bleaching sensitivity was collected through a form composed of the visual analogue scale (vas). color measurement was performed at two times: baseline (ti) and one week after the 3rd bleaching session (tf).


Eligibility criteria:
inclusion criteria: * good oral hygiene * absence of active caries lesions * never having undergone previous whitening therapy * not present dental hypersensitivity * don't be a smoker * not be pregnant * present at least 28 teeth in the oral cavity. exclusion criteria: * volunteers who were under orthodontic treatment, * presence of periodontal disease * dental cracks or fractures * restorations and prostheses on anterior teeth * extensive molar restorations * gastroesophageal disorders * severe internal dental darkening * presence of dentinal exposure in anterior and / or posterior teeth.
predictive factors of good results after multiligamentar knee reconstruction (mlkr)

Conditions: Knee Ligament Injury

Summary: multiligamentar knee injury has consequences on knee function (instability, arthritis, life disagreement). surgical reconstructions have known recent evolutions. the goal of this study is to evaluate functional and clinical results at one year of those new surgical technics. a clinical and functional follow up will be performed before the surgery, then at 6 months and one year.

patients will also benefit of a magnetic resonance imaging (mri) and isokinetic evaluations at one year.

Eligibility criteria:
inclusion criteria: * any patient who benefits of a multiligamentar knee reconstruction at hospital of saint-etienne exclusion criteria: * refusal

Keywords: multiligamentar injury knee magnetic resonance imaging (mri) knee reconstruction knee dislocation
data collection of normal tissue toxicity for proton therapy for pediatrics

Conditions: Pediatric Cancer

Summary: the goal of this research study is to collect information on the side effects of proton therapy and the details of proton treatment plans so that researchers can develop a method to predict the risk of side effects and to improve the planning and delivery of proton treatment for patients in the future.

if you agree to take part in this study, researchers will gather information about your treatment and treatment outcomes and store it electronically in a database. by carefully evaluating the data about your treatment, researchers may improve proton treatment for patients in the future. there will be no change to your recommended standard of care and follow-up studies. the treatment information and follow-up information will be stored in a database. the information will then be available at a later date for researchers to study. the database will be stored on a secure information network, and only those people who are involved with this research and who have prior approval from the study doctor will have access to it. researchers will request information from the follow-up visits that you have as part of your standard of care yearly or more often and test results for at least 10-15 years. the tests may be performed at other clinics, but md anderson researchers will request that the results be sent to them at md anderson. this is an investigational study. proton radiotherapy is fda approved. researchers hope to enroll all children who will be treated with proton radiotherapy at md anderson on this study so that as much information as possible will be gathered. up to 1000 patients will be enrolled at md anderson.

Eligibility criteria:
inclusion criteria 1. all patients under the age of 18 who are treated with pbt will be eligible to participate in this trial. 2. signed informed consent must be obtained from the patient or patient's representative prior to study enrollment. exclusion criteria: 1. pregnant females are not eligible. 2. patient or patient's parent or legal guardian representative is unable or unwilling to give informed consent.

Keywords: pediatric cancer proton radiation therapy proton beam radiotherapy pbt data collection database acute and late normal tissue toxicities dosimetric data toxicity data
the combination of tacrolimus and danazol as the treatment of steroid-resistant/relapse immune thrombocytopenia

Conditions: Immune Thrombocytopenia

Summary: randomized, open-label, multicenter study to compare the efficacy and safety of combination of tacrolimus and danazol versus danazol for the treatment of adults with steroid-resistant/relapse immune thrombocytopenia (itp).

the investigators are undertaking a randomized controlled trial of 120 adults with steroid-resistant/relapse itp in china. patients were randomized to tacrolimus plus danazol and danazol monotherapy group. platelet count, bleeding and other symptoms were evaluated before and after treatment. adverse events are also recorded throughout the study.

Eligibility criteria:
inclusion criteria: * primary immune thrombocytopenia (itp); * 18 years older; * platelet count of less than 30×10\^9/l at enrollment; * patients who did not achieve a sustained response to treatment with full-dose corticosteroids for a minimum duration of 4 weeks or who relapsed during steroid-tapering or after its discontinuation; * patients who were receiving other maintenance regimens, primarily corticosteroids, ciclosporin, or mycophenolate mofetil, were also eligible if the dose of treatment had been stable in the past month and the dose was expected to be stable after enrolment and remained unchanged at least for the first 4 weeks of study until initial response was assessed, unless severe adverse events were suspected. exclusion criteria: * secondary itp (e.g., patients with hiv, hbv, hcv, helicobacter pylori infection or sle); * congestive heart failure, severe arrhythmia; * nursing or pregnant women; * alt or ast levels ≥ 3× the upper limit of the normal threshold; * creatinine or serum bilirubin levels ≥ 1.5× the upper limit; * active or previous malignancy ; * patients who had received danazol treatment or did not respond to danazol; * patients unable to have routine blood tests because of reasons such as insufficient time.

Keywords: immune thrombocytopenia tacrolimus danazol
comparison of oxygen delivery devices for reversal of altitude-induced hypoxemia in normal subjects

Conditions: Hypoxemia; Hypobaric Hypoxemia

Summary: this study will compare the ability of pulsed-dose oxygen from a concentrator to reverse altitude-induced hypoxemia compared to compressed gas from a standard oxygen cylinder.

subjects will be monitored non-invasively with pulse oximetry, end-tidal carbon dioxide, tissue oxygenation and ecg. the mean seal level oxygen saturation will be recorded.subjects exposed to an altitude of 14,000 feet will experience moderate hypobaric hypoxia. the mean oxygen saturation at this altitude is 83%. subjects will receive oxygen from both an oxygen concentrator or a cylinder of oxygen following exposure to hypobarism. oxygen from each source will be increased in 1 liter per minute increments until the oxygen saturation returns to the baseline sea level oxygen saturation. the oxygen requirement to return oxygen saturation to baseline values will be recorded. the flow from the concentrator and the cylinder will be compared.

Eligibility criteria:
inclusion criteria: * current altitude chamber certification * age 18 years - 60 years exclusion criteria: * current upper respiratory infection * current symptoms of lower respiratory infection -- productive cough

Keywords: hypobaric hypoxemia altitude oxygen oxygen concentrator